DMUC5754A showed an acceptable safety profile, with main adverse events being fatigue, peripheral neuropathy, and nausea, and demonstrated early anticancer activity, especially in patients with high MUC16 expression [122]. The gene discussed is MUC16; the disease is peripheral neuropathy.